egfr & alk/ros1 testing in squamous nsclc
Published 7 years ago • 1.5K plays • Length 8:25Download video MP4
Download video MP3
Similar videos
-
1:10
dr. gubens on prevalence of egfr/alk/ros1 and pd-l1 expression in nsclc
-
4:09
plasma testing for nsclc egfr & alk mutations
-
1:06
dr. goldman on targeted therapy options for egfr-, alk-, and ros1-mutated nsclc
-
9:30
egfr testing for nsclc
-
4:27
molecular testing beyond egfr and alk in stage iv nsclc
-
1:04
molecular testing in egfr mutant driven nsclc
-
7:07
mutation testing in nsclc
-
7:09
pd-l1 testing in squamous nsclc
-
5:53
targeted therapy in non-small cell lung cancer
-
4:49
emerging alk/ros1 tkis for nsclc
-
1:00
uncommon egfr mutations in metastatic non-small cell lung cancer.
-
7:31
mutation testing to guide alk tki selection in nsclc
-
7:46
egfr and pd-l1 testing in locally advanced nsclc
-
4:05
the evolution of alk/ros1-targeted therapy in nsclc
-
3:30
lung cancer targeted gene panel with rearrangement [a test in focus]
-
4:07
chemotherapy with i-o therapy in egfr- or alk-mutated nsclc
-
3:55
treatment considerations in alk/ros-1–rearranged nsclc
-
5:21
molecular testing and actionable targets in lung cancer
-
5:13
current mutation testing in lung cancer